MX2022001211A - Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso. - Google Patents

Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.

Info

Publication number
MX2022001211A
MX2022001211A MX2022001211A MX2022001211A MX2022001211A MX 2022001211 A MX2022001211 A MX 2022001211A MX 2022001211 A MX2022001211 A MX 2022001211A MX 2022001211 A MX2022001211 A MX 2022001211A MX 2022001211 A MX2022001211 A MX 2022001211A
Authority
MX
Mexico
Prior art keywords
molecules
amino acid
hla class
methods
mhc class
Prior art date
Application number
MX2022001211A
Other languages
English (en)
Spanish (es)
Inventor
Naoto Hirano
Kenji Sugata
Tingxi Guo
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2022001211A publication Critical patent/MX2022001211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
MX2022001211A 2019-07-30 2020-07-29 Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso. MX2022001211A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880509P 2019-07-30 2019-07-30
US202063029115P 2020-05-22 2020-05-22
PCT/IB2020/057174 WO2021019474A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022001211A true MX2022001211A (es) 2022-05-03

Family

ID=74230294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001211A MX2022001211A (es) 2019-07-30 2020-07-29 Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.

Country Status (12)

Country Link
US (1) US20220281949A1 (cg-RX-API-DMAC10.html)
EP (1) EP4004033A4 (cg-RX-API-DMAC10.html)
JP (1) JP7811541B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220052944A (cg-RX-API-DMAC10.html)
CN (1) CN114502580B (cg-RX-API-DMAC10.html)
AU (1) AU2020319732B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022001702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146296A1 (cg-RX-API-DMAC10.html)
IL (1) IL290231A (cg-RX-API-DMAC10.html)
MX (1) MX2022001211A (cg-RX-API-DMAC10.html)
TW (1) TW202118781A (cg-RX-API-DMAC10.html)
WO (1) WO2021019474A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
TWI881991B (zh) * 2019-07-30 2025-05-01 大學健康網絡 Ｉｉ類ｍｈｃ分子及其使用方法
TW202116797A (zh) 2019-07-30 2021-05-01 大學健康網絡 Ｉｉ類ｍｈｃ分子及其使用方法
CN118662607B (zh) * 2023-03-15 2026-07-07 中国科学院上海药物研究所 抑制过激炎性反应的蛋白及其应用
US20250074966A1 (en) * 2023-08-31 2025-03-06 Adaptive Biotechnologies Corporation Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601801B2 (en) * 2003-07-11 2009-10-13 Dainippon Sumitomo Pharma Co., Ltd. HLA-A24 binding cancer antigen peptide derived from livin
US20060228758A1 (en) * 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9738724B2 (en) * 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9717758B2 (en) * 2013-05-17 2017-08-01 University Of Massachusetts High-affinity DMF5 T cell receptor (TCR) variants
WO2016135363A1 (es) * 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
MX2018006789A (es) * 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
US12187781B2 (en) * 2018-08-01 2025-01-07 Regents Of The University Of Minnesota Co-receptor affinity enhanced major histocompatibility class II molecules

Also Published As

Publication number Publication date
AU2020319732B2 (en) 2026-07-09
EP4004033A4 (en) 2023-12-06
US20220281949A1 (en) 2022-09-08
BR112022001702A2 (pt) 2022-06-21
TW202118781A (zh) 2021-05-16
CA3146296A1 (en) 2021-02-04
JP2022542448A (ja) 2022-10-03
EP4004033A1 (en) 2022-06-01
WO2021019474A1 (en) 2021-02-04
CN114502580B (zh) 2025-10-17
IL290231A (en) 2022-03-01
KR20220052944A (ko) 2022-04-28
JP7811541B2 (ja) 2026-02-05
CN114502580A (zh) 2022-05-13
AU2020319732A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112022001702A2 (pt) Moléculas mhc classe ii e métodos de uso das mesmas
NZ606584A (en) Binding proteins for hepcidin
AU2017248122A1 (en) T cell receptors
BR112022012057A2 (pt) Novos métodos de entrega celular
BR112022001710A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
MY170306A (en) Method for activating helper t cell
AU2018280528A8 (en) Method for improving transformation efficiency of plant and method for transforming plant
MX2022015376A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
UA105193C2 (ru) Вектор, содержащий две гомологические нуклеотидные последовательности
EP4374913A3 (en) Novel human serum albumin mutant
MX2022001033A (es) Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células.
BRPI0516176A (pt) polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina
EP4596696A3 (en) Compositions and methods for nucleic acid modifications
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
MX2023001083A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
MX2021002672A (es) Proceso mejorado para la preparación de proteína recombinante.
EA033437B1 (ru) Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний
WO2022235577A3 (en) T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
MX2022001208A (es) Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.
NZ596300A (en) Fviii-derived peptides
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
MX2020013158A (es) Proteina cas9 modificada y uso de la misma.